Ikarovec is developing a portfolio of novel gene therapies targeting major ophthalmic indications. Its lead program is a multicistronic gene therapy for diabetic macular edema (DME) currently at IND-enabling studies. Other programs target wet age-related macular degeneration, dry AMD and intra-ocular hypertension. The company plans to use the new funds to advance three earlier-stage products, build its intellectual property portfolio and establish its own laboratories. Ikarovec was founded in 2019 by Dr Peter Widdowson around IP spun out of Quethera and is led by Executive Chairman Dr Robert Haigh. The company is based in Cambridge, UK.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Feb 2020